|
Patients with retinoblastoma are at risk for developing secondary malignant neoplasms (SMNs). A carefully designed treatment protocol that is individualized for each patient can reduce the risk of SMNs and improve the outcome. Therapeutic advances and clinical trials have improved the prognosis. However, the selected course of therapy is dependent upon many factors, such as whether the disease is bilateral or unilateral, familial or sporadic, the size and location of the tumor within the eye, and the child's age.
|